Industry
Biotechnology
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Loading...
Open
3.87
Mkt cap
19M
Volume
57K
High
3.90
P/E Ratio
-1.18
52-wk high
8.85
Low
3.20
Div yield
N/A
52-wk low
2.15
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 9:39 am
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 12:35 pm
Portfolio Pulse from Benzinga Insights
October 15, 2024 | 4:32 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 2:34 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 5:50 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:41 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 5:34 pm
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 2:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.